Eli Lilly Reports Strong Third Quarter Performance Exceeding Market Expectations

Eli Lilly has reported a strong performance for its third quarter, exceeding market expectations and upgrading its full-year sales forecast. The pharmaceutical company's revenue surged past estimates, driven by continued demand for its weight loss medication Zepbound and diabetes treatment Mounjaro.

While the sales of its new GLP-1 obesity pill Foundayo fell short of Wall Street's projections for the quarter, the overall performance of the company was impressive. This is particularly noteworthy considering that other pharmaceutical companies have struggled to match Lilly's success in the weight loss market.

Lilly has revised its full-year revenue guidance upwards, predicting sales will range between $91 billion and $92 billion. This represents a significant increase from its previous estimate of $85 billion to $87 billion. The company also expects adjusted earnings per share to fall between $35 and $36, a slight decrease from its earlier forecast.

The upgrade in Lilly's full-year outlook is a testament to the enduring popularity of Zepbound and Mounjaro. However, the company has taken charges tied to deals worth $4.57 per share, which will offset some of the increased profit guidance. As a result, Lilly's shares have risen by about 4% in premarket trading.

Eli Lilly's diabetes and obesity medicines continue to be a major driver of growth for the company, despite facing lower net prices in the US market. This trend is evident in the strong demand for Zepbound and Mounjaro, two key products that have been instrumental in Lilly's success.

The pharmaceutical giant has seen its profits from these medications translate into deal-making activity, with a recent agreement to acquire Merida Biosciences aiming to develop new treatments for serious autoimmune and allergic diseases. This move underscores Lilly's focus on expanding its portfolio of innovative therapies.

Mounjaro's revenue has been particularly impressive, with worldwide sales reaching $10.72 billion in the third quarter, a 65% increase from the same period last year. This far exceeded analysts' expectations, which had predicted worldwide sales of $10.10 billion and US revenue of $4.79 billion.

Expanded coverage for obesity care is also playing a role in Lilly's success, with Medicare starting to cover GLP-1s for weight loss under a temporary pilot program launched in July. This development has contributed to the strong performance of Zepbound and Mounjaro, which have seen significant demand despite lower US prices.

Zepbound's strong performance has continued to drive sales, with the medication generating $5.35 billion in revenue for the third quarter. This represents a significant 49% increase from the year-earlier period, despite a drop in realized prices.

The majority of Zepbound's sales come from the US market, where demand for the drug remains high. Analysts had forecasted lower global sales for Zepbound, estimating $5.09 billion in revenue, including $4.99 billion from the US alone.

In contrast to Zepbound's success, Eli Lilly's new obesity pill, Foundayo, has struggled to meet expectations. Launched in April after winning US approval, Foundayo generated $184 million in sales for the third quarter, falling short of analyst forecasts of around $229 million.

Foundayo is not the only GLP-1 medication on the market, with a rival oral drug from Novo launching in January and competing directly with it. This increased competition has likely contributed to the lower-than-expected sales figures for Foundayo.

Eli Lilly's international sales saw a significant surge in the third quarter, rising 47% to reach $9.3 billion. This growth was driven by a substantial increase in volume, which jumped 76%, although it was partially offset by a decline in realized prices of 29%.

The pharmaceutical company reported a net income of $6.45 billion for the quarter, translating to earnings per share of $7.22. Adjusted for one-time items related to intangible assets and other adjustments, Eli Lilly's earnings per share came out at $7.48.